GlassScriptPhysician profile
Roger R Wang
NPI 1164522165
$9,573.95
in general payments reported to CMS, 2019-2025
14 companies · $2,032 in 2025
The $2,032 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $309 · 2021: $437 · 2022: $1,412 · 2023: $2,507 · 2024: $2,249 · 2025: $2,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,700 · Education: $87.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,700.10 |
| Education | $87.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $6,338.80 | 2022-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,911.24 | 2019-2025 | |
| Pfizer INC. | $482.48 | 2023-2024 | |
| Lilly USA, LLC | $180.36 | 2019 | |
| Abbvie INC. | $153.27 | 2021-2025 | |
| Amgen INC. | $109.33 | 2025 | |
| Genzyme Corporation | $97.05 | 2025 | |
| Ucb, INC. | $78.29 | 2023-2025 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Bioventus LLC | $54.35 | 2019 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Galderma Laboratories, L.P. | $24.24 | 2025 | Nemluvio |
| Stryker Corporation | $23.25 | 2020 | |
| Glaxosmithkline, LLC. | $22.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.